PeptidePilotEducational tools

LEARN FROM THIS PROTOCOL · CASE STUDY 01

Hear the reasoning.
Follow the evidence.

A confident video can leave you with a lot of questions. Explore the proposed stack, examine its claims, and build a clearer picture of the decision.

Explore the stackExamine the claims
5peptides discussed6claims examined1curated video review

Source review, not a treatment plan. This is an editorial assessment of one supplied video and selected research. A finding about an ingredient does not establish the benefit or safety of the whole stack. Sources checked October 15, 2026.

01 / EXPLORE THE PROPOSED STACK

What does each addition bring?

Click a name to inspect it. Check or uncheck ingredients to change the comparison.

Interactive comparison
01

Metabolic target

02

Cellular research

03

GH / IGF-1 axis

5/ 5ingredients included
10pairs in this selection
4pairs flagged for review
6pair evidence gaps

Counts describe evidence coverage, not estimated risk.

Open all 10 pair checks
COMBINATION EVIDENCE

Specific issues need review

This selection has a concern or trial-specific evidence worth examining. The decision brief connects the rationale, research and reported experiences.

Make sense of this selectionRationale, evidence & practical questions

5 peptides · 10 pairs checked

4 for review6 insufficient evidence
Retatrutide + TesamorelinDifferent targets; glucose review matters
Individual-drug evidence; combination inference

Retatrutide has weight and glucose effects in trials. Tesamorelin targets the GH / IGF-1 axis and carries glucose-intolerance and fluid-retention warnings. Different targets explain the rationale, but do not establish compatibility; do not assume one drug cancels the other's glucose effects. Added benefit and safety of this pair remain unestablished.

CJC-1295 + IpamorelinOverlapping growth-hormone effects
Mechanism-based concern

Both act on the GH / IGF-1 axis. Combined endocrine effects may be amplified. This is an inference from their mechanisms, not proof of a specific pair interaction; a clinician must assess the combination.

CJC-1295 + TesamorelinOverlapping growth-hormone effects
Mechanism-based concern

Both act on the GH / IGF-1 axis. Combined endocrine effects may be amplified. This is an inference from their mechanisms, not proof of a specific pair interaction; a clinician must assess the combination.

Ipamorelin + TesamorelinOverlapping growth-hormone effects
Mechanism-based concern

Both act on the GH / IGF-1 axis. Combined endocrine effects may be amplified. This is an inference from their mechanisms, not proof of a specific pair interaction; a clinician must assess the combination.

MOTS-c + RetatrutideInsufficient combination evidence
Not established by this reference

This reference cannot establish the safety of this pair. Missing interaction evidence is not evidence of safety. Ask a pharmacist or prescriber to review the exact products and your full medication list.

CJC-1295 + RetatrutideInsufficient combination evidence
Not established by this reference

This reference cannot establish the safety of this pair. Missing interaction evidence is not evidence of safety. Ask a pharmacist or prescriber to review the exact products and your full medication list.

Ipamorelin + RetatrutideInsufficient combination evidence
Not established by this reference

This reference cannot establish the safety of this pair. Missing interaction evidence is not evidence of safety. Ask a pharmacist or prescriber to review the exact products and your full medication list.

CJC-1295 + MOTS-cInsufficient combination evidence
Not established by this reference

This reference cannot establish the safety of this pair. Missing interaction evidence is not evidence of safety. Ask a pharmacist or prescriber to review the exact products and your full medication list.

What does the community say?Read reported experiences & original discussions

This is a curated educational reference, not a validated interaction database. Pair checks cannot predict effects of a whole stack. Dose, route, other medicines and medical history are not assessed. This does not assess mixing in one vial or syringe. Take your selection to a pharmacist or prescriber.

WHAT TO NOTICE

3 selected ingredients share the GH axis.

Different names do not necessarily mean independent effects. Review what each adds and how shared GH / IGF-1 activity could matter. This is a mechanism-based concern, not a measured interaction rate.

Read this selection’s decision brief
REPORTED IN THE VIDEO

The creator describes a client losing over 35 lb and reaching roughly 7–8% body fat.

Creator-reported; not independently verified here. A client account cannot identify each compound’s contribution.0:38 · Hear the account
02 / EXAMINE THE CLAIMS

Keep the explanation. Examine the claim.

Each assessment identifies the evidence, its scope, and what it can contribute to a decision.

Original video claims

Showing 6 of 6 claims. These assessments concern the original video; the comparison above is separate.

01Supported in a studied settingVIDEO CLAIM · PARAPHRASED

Retatrutide has a visceral-fat rationale.

A human study supports the target. It does not establish the value of the full stack.
WHAT THE RESEARCH CAN SAY

In a randomized substudy of 98 participants with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), retatrutide reduced abdominal visceral fat versus placebo. Imaging and follow-up limitations matter when interpreting the results.

Single drug · selected population · no five-peptide comparison
WHAT THIS MEANS FOR A DECISION

There is an evidence-based reason to discuss this target. To justify another compound, the useful question is what it adds beyond the existing treatment.

2:35 · Original discussionSanyal et al. · Nature Medicine, 2024
02Preclinical rationaleVIDEO CLAIM · PARAPHRASED

MOTS-c complements the metabolic target.

The research is interesting; the cited work is in cells and animals.
WHAT THE RESEARCH CAN SAY

The 2015 MOTS-c paper describes metabolic signaling and treatment effects on insulin resistance and diet-induced obesity in mice. It does not demonstrate an added human fat-loss benefit from combining injected MOTS-c with retatrutide.

Preclinical work · human combination benefit not established by this source
WHAT THIS MEANS FOR A DECISION

A plausible mechanism can motivate research. It cannot tell a reader the likely benefit, adverse-event rate or appropriate treatment plan for this combination.

4:10 · Original discussionPreclinical study · MOTS-c and metabolism
03Hormone effect shown; outcomes differVIDEO CLAIM · PARAPHRASED

GH stimulation supports recovery and muscle preservation.

A hormone change and a meaningful recovery benefit are different outcomes.
WHAT THE RESEARCH CAN SAY

Short CJC-1295 trials showed sustained increases in GH and IGF-1. Their primary outcomes were hormone concentrations and pharmacokinetics, not injury prevention, long-term muscle preservation or this stack's safety. The long-acting formulation studied also matters.

Long-acting CJC-1295 · short studies · not the three-drug GH stack
WHAT THIS MEANS FOR A DECISION

CJC-1295, ipamorelin and tesamorelin all concern the GH axis. Shared downstream activity is a reason to review possible amplification; it is a mechanism-based concern, not a measured interaction rate.

6:07 · Original discussionHuman study · CJC-1295 and GH / IGF-1Preclinical study · Ipamorelin as a GH secretagogueDailyMed · Egrifta WR prescribing information
04Supported in a studied settingVIDEO CLAIM · PARAPHRASED

Tesamorelin targets visceral fat.

Human evidence exists, including a small study outside HIV-associated lipodystrophy.
WHAT THE RESEARCH CAN SAY

A randomized 12-month trial in 60 adults with abdominal obesity and reduced GH secretion found lower visceral fat and higher IGF-1 with tesamorelin. That selected population does not represent everyone seeking a leaner abdomen.

Single drug · defined population · not evidence of added benefit with retatrutide
WHAT THIS MEANS FOR A DECISION

Ask whether the studied target and population match the proposed use. Glucose, IGF-1, fluid retention and contraindications remain relevant to an individual assessment.

8:16 · Original discussionHuman trial · Tesamorelin in abdominal obesity (2012)DailyMed · Egrifta WR prescribing information
05Personal and coaching experienceVIDEO CLAIM · PARAPHRASED

The five-peptide protocol reliably delivers results.

A reported outcome can start a useful inquiry; it does not isolate each ingredient's effect.
WHAT THE RESEARCH CAN SAY

The reviewed material does not supply a comparison group or independently verified dataset for the five-drug protocol. Diet, exercise and other changes complicate attribution. The linked single-drug studies do not fill that gap.

Use report and coaching opinion · no whole-stack trial supplied
WHAT THIS MEANS FOR A DECISION

Keep the account visible, then ask for the baseline, follow-up measurements, other treatments and unwanted effects. Those details help assess how much the experience can inform another person's decision.

14:00 · Original discussionSanyal et al. · Nature Medicine, 2024Human study · CJC-1295 and GH / IGF-1Human trial · Tesamorelin in abdominal obesity (2012)
06Contradicted by human evidenceVIDEO CLAIM · PARAPHRASED

Calorie restriction cannot reduce visceral fat.

This categorical claim conflicts with randomized human evidence.
WHAT THE RESEARCH CAN SAY

In the 16-week DOSE-EX trial analysis, calorie restriction reduced visceral-fat volume versus standard care in people with type 2 diabetes. The group with the highest exercise volume had a larger reduction than diet alone.

Randomized-trial secondary analysis · type 2 diabetes population
WHAT THIS MEANS FOR A DECISION

A proposed peptide strategy should be considered alongside effective lifestyle approaches. A claim that diet cannot affect visceral fat should not be the reason someone adds drugs.

1:54 · Original discussionHuman trial · DOSE-EX fat-loss analysis
Go straight to a discussion in the video
2:35Metabolic target4:10Cellular rationale6:07Growth-hormone pathway8:16Visceral-fat target9:34Stacking discussion11:10Lifestyle context
03 / YOUR CURRENT COMPARISON

The brief and community view below follow your 5-ingredient selection. Pair counts describe coverage, not the probability of benefit or harm.

CONNECT THE EVIDENCE TO THE DECISION

Your decision brief.

Why people consider it. What supports it. What needs a closer look.

Editorial synthesis · October 15, 2026
CJC-1295 + Ipamorelin + MOTS-c + Retatrutide + Tesamorelin

Review the shared pathway before looking for synergy.

CJC-1295 + Ipamorelin has overlapping activity. Ask what the second compound adds beyond the first, and how amplified effects would be assessed. The overlap is a mechanism-based concern, not a measured interaction rate.

01 / THE RATIONALE

Why combine them?

People may be combining different goals or trying to reinforce one effect. The individual purposes below explain the starting point. They do not establish a benefit from using the whole selection together.

Sources for the rationale
Human study · CJC-1295 and GH / IGF-1FDA · Compounded peptide safety risksPreclinical study · Ipamorelin as a GH secretagoguePreclinical study · MOTS-c and metabolismClinicalTrials.gov · Retatrutide, TRIUMPH-1FDA · Unapproved GLP-1 products and investigational peptidesDailyMed · Egrifta WR prescribing information
02 / THE RESEARCH

What does it support?

The linked sources vary from approved-product trials to small human studies and animal work. Evidence for one ingredient or a different formulation cannot establish what this selection adds. Open the profiles below to see the scope for each.

Open the research sources
Human study · CJC-1295 and GH / IGF-1FDA · Compounded peptide safety risksPreclinical study · Ipamorelin as a GH secretagoguePreclinical study · MOTS-c and metabolismClinicalTrials.gov · Retatrutide, TRIUMPH-1FDA · Unapproved GLP-1 products and investigational peptidesDailyMed · Egrifta WR prescribing information
03 / THE EXPERIENCE

What do people report?

About a subset of your selection: Retatrutide + Tesamorelin

People do report using this pair and perceiving better body composition. Hunger and reflux also appear in the discussions; the added benefit is not isolated.

Read the reports & their context 6 selected threads linked · no success rate inferred
Closer look: research & a physician’s perspectiveAbout the retatrutide + tesamorelin pair within your selection · individual-drug evidence
Randomized human trial

Retatrutide can reduce body weight

The 2023 obesity trial found substantial weight reduction over 48 weeks. Gastrointestinal effects were common and heart-rate increases were observed. Tesamorelin was not part of the tested treatment.

Retatrutide alone · not this pair
Human trial · Retatrutide for obesity (2023)
Randomized human trial

Tesamorelin research extends beyond HIV

A 12-month trial in 60 adults with abdominal obesity and reduced GH secretion found reduced visceral fat and increased IGF-1, without significant changes in fasting glucose or HbA1c. It does not represent all adults seeking fat loss.

Tesamorelin alone · selected population
Human trial · Tesamorelin in abdominal obesity (2012)
Randomized human trial

Glucose findings deserve context

A 12-week trial in 53 people with type 2 diabetes found no significant between-group difference in insulin response or overall glycemic control. This is reassuring within that study, alongside the glucose warning in prescribing information.

Tesamorelin alone · short follow-up
Human trial · Tesamorelin in type 2 diabetes (2017)
Physician perspective · Peter Attia, MD

A conditional clinical perspective

Attia considers tesamorelin potentially worth considering when using the approved product, tracking IGF-1 and glucose, and measuring progress toward the intended outcome. His discussion does not evaluate a retatrutide combination.

Opinion about tesamorelin · not a pair recommendationOriginal physician commentary on a site offering paid memberships. This is a perspective, not a trial or a claim of medical consensus.
Peter Attia, MD · Peptide evidence and tesamorelin commentary

The physician perspective is included for its reasoning, with its scope and commercial context visible. It does not establish agreement among clinicians. The studies are a selected reading list, not a systematic review.

A MORE USEFUL NEXT STEP

Three questions that change the decision.

Use these to have a specific conversation with a clinician who understands the proposed treatment.

  1. Name the extra benefit

    Is the goal weight loss, visceral-fat reduction or preserving muscle? Ask how that outcome would be measured and what would count as meaningful improvement over the current treatment.

    Human trial · Retatrutide for obesity (2023)Human trial · Tesamorelin in abdominal obesity (2012)

  2. Discuss glucose and IGF-1

    Ask which baseline and follow-up glucose / HbA1c and IGF-1 checks are appropriate. Retatrutide's glucose effects cannot be assumed to cancel tesamorelin's risks. Include swelling, joint symptoms and changes in hunger in the discussion.

    DailyMed · Egrifta WR prescribing informationHuman trial · Retatrutide in type 2 diabetes (2023)

  3. Check reasons to rule it out

    Tesamorelin is contraindicated with active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy, or known hypersensitivity to the product. Review cancer history, all medicines and the exact product with the clinician.

    DailyMed · Egrifta WR prescribing information
Review the individual purposes, evidence and concerns

TesamorelinLabeled use

PurposeEgrifta reduces excess abdominal fat in adults with HIV-associated lipodystrophy.

EvidenceThis indication is specific; it is not approved for general weight management.

ConcernsElevated IGF-1, fluid retention and glucose intolerance; contraindicated with active malignancy.

DailyMed · Egrifta WR prescribing information

Educational decision support, not individualized medical advice or a safety clearance. No dose, schedule, product quality or personal medical history has been evaluated. Clinical studies, professional opinions and community reports carry different evidentiary weight.

EXPERIENCE, IN PEOPLE'S OWN WORDS

What the community says.

Reported benefits. Frustrations. Experiences that don't match the hype.
A separate look at public discussions, alongside the clinical evidence above.

Anecdotal · Curated
COMMUNITY VIEW FOR

Retatrutide + MOTS-c + CJC-1295 + Ipamorelin + Tesamorelin

See your decision briefSearch this whole stack

3 of 10 pairs have curated summaries·6 original threads linked

Pair experiences do not establish how the full stack behaves. Cards identify whole-stack mentions, pair reports and related larger stacks separately.

Body-composition discussions4 threads

Retatrutide + Tesamorelin

Pair within your selection

People do report using this pair and perceiving better body composition. Hunger and reflux also appear in the discussions; the added benefit is not isolated.

Reported upsides

A 26-week update describes better appearance, recovery and maintained strength with regular training. A four-month poster perceives muscle preservation, and another reports short-term weight loss while also following a low-carb diet. [1][2][3]

Reported downsides

The early-results author describes temporarily increased food noise; a reply describes marked heartburn / reflux with this pair. A separate larger-stack report describes intense hunger, but also includes ipamorelin, MOTS-c and endurance training. [3][4]

Read this in context

These are four selected threads, not four verified independent experiments. Photos and perceived muscle preservation are not measured visceral-fat or lean-mass outcomes. The early-results author's proposed glucose balancing and ketone-based fat-loss explanations are unverified. The ipamorelin report concerns a larger stack.

Read 4 original discussions
  1. Week 26 update: retatrutide plus tesamorelinr/Retatrutide · checked October 15, 2026
  2. Four-month retatrutide + tesamorelin updater/Retatrutide · checked October 15, 2026
  3. Using tesamorelin with retatrutide: early results and repliesr/Retatrutide · checked October 15, 2026
  4. Tesamorelin / ipamorelin, MOTS-c and retatrutider/Biohackers · checked October 15, 2026
Training & recovery discussions1 thread

CJC-1295 + Ipamorelin

Pair within your selection

One detailed update reports strength and muscle gains, with less fat loss than hoped and noticeable bloating.

Reported upsides

The author reports getting stronger, looking more muscular and experiencing better shoulder mobility over a 90-day period. [1]

Reported downsides

The same author describes bloating and disappointing fat loss. Their torn labrum still needed surgery. [1]

Read this in context

One author's update. Training and alcohol use are part of the story, and the post does not establish which CJC formulation was responsible for any effect.

Read the original discussion
  1. 90-day update: CJC-1295 / ipamorelinr/Peptides · checked October 15, 2026
Related GH-stack experiences2 threads

Tesamorelin + Ipamorelin

Pair within your selection

People describe trying this pair for recovery or body composition, with mixed sleep, hunger and water-retention experiences.

Reported upsides

A commenter using tesamorelin / ipamorelin alongside tirzepatide reports somewhat better sleep; other commenters describe perceived body-composition benefits. [1]

Reported downsides

A retatrutide user describes intense hunger after adding the pair. A tirzepatide user reports water-weight gain and little additional benefit. [2][1]

Read this in context

Both source discussions include a GLP-1-active drug. They are larger-stack experiences and cannot isolate the effects of tesamorelin plus ipamorelin.

Read 2 original discussions
  1. Tirzepatide / tesamorelin experiencesr/Peptidesource · checked October 15, 2026
  2. Tesamorelin / ipamorelin, MOTS-c and retatrutider/Biohackers · checked October 15, 2026

Explore the remaining pairs

These pairs do not have an isolated-pair summary in this edition. Related larger-stack reports, if shown, are context only.

MOTS-c + RetatrutideSearch discussionsCJC-1295 + RetatrutideSearch discussionsIpamorelin + RetatrutideSearch discussionsCJC-1295 + MOTS-cSearch discussionsIpamorelin + MOTS-cSearch discussionsMOTS-c + TesamorelinSearch discussions
How to read community reports

Anecdotes can surface questions and patterns. They cannot tell us how often a benefit or side effect happens, or whether a combination caused it. Repeated posts may come from the same person, and positive stories can be amplified by sellers, affiliates or selection bias.

These are editorial summaries of selected public threads, including favorable, disappointing and adverse experiences where found. Authors, diagnoses, product contents and outcomes are unverified. Thread counts count linked discussions, not people, independent confirmations or success rates. A missing adverse report is not evidence of safety.

Each card links its claims to the original discussion and identifies extra compounds or other relevant context. No safety score or treatment protocol is derived from forum reports. The clinical review above remains a separate source of information.

Curated public discussions · checked October 15, 2026This is a selected reading list, not a live feed or an exhaustive survey.
TAKE THE QUESTIONS WITH YOU

Make the next conversation useful.

Choose questions for a portable note with your comparison, individual concerns and source links. These choices organize the note; they do not complete a medical assessment.

5 peptides included · 4 questions selected

FOLLOW THE ORIGINAL MATERIAL

Sources & review scope.

Selected primary research and product information. This is not an exhaustive search or a systematic review.

Video statements are brief editorial paraphrases from its public transcript. Names were normalized against the peptide catalog; transcript wording can contain errors. Timestamps link to the original for context. This review does not reproduce or validate the creator’s dosing, sequencing or cycling instructions. Individual-product studies do not establish research-vial quality or whole-stack outcomes.